Exhibit 99.1

 

LOGO

NEWS RELEASE - for immediate release

Alexza Reports Fourth Quarter and Year End 2014 Financial Results

Management to Review Results and Provide General Update in Conference Call Scheduled Today for 5:00 p.m. Eastern Time

Mountain View, California - March 9, 2015 -

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter and year ended December 31, 2014. The net loss for the fourth quarter was $6.7 million compared to $5.7 million during the same quarter in 2013. The net loss for the years ended December 31, 2014 and 2013 was $36.7 million and $39.6 million, respectively. At December 31, 2014, Alexza had consolidated cash, cash equivalents, marketable securities, and restricted cash of $37.5 million.

“During 2015 and beyond, we see several value opportunities for Alexza,” said Thomas B. King, President and CEO of Alexza. “We believe we will see continued uptake of ADASUVE® , based on the foundation established by Teva in the U.S., and Ferrer in the EU and Latin America. Teva and Ferrer continue to make progress with the number of hospitals and physicians utilizing ADASUVE. We continue to feel confident about the long-term potential of ADASUVE, given the satisfaction we hear from doctors and patients who have used the product and found it to be safe and effective.”

King continued, “Beyond ADASUVE, we are excited about our evolving pipeline, with a goal of deriving value from our Staccato® technology. We have two product candidates in active development. We initiated a Phase 2a study with AZ-002 (Staccato alprazolam) in a subset of epilepsy patients. Additionally, in 2015 we expect to commence a Phase 2 clinical trial with AZ-007 (Staccato zaleplon) for the treatment of middle of night awakening.”

Alexza Business Updates

 

    During the fourth quarter, Ferrer began marketing ADASUVE in three additional EU countries, bringing the total to 12 countries where ADASUVE is being marketed in the EU. As of March 2015, Ferrer has received ADASUVE approval in seven Latin American countries and currently markets the product in Guatemala. Ferrer anticipates additional EU Member States and Latin American country approvals and launches in 2015 and 2016.

 

    During the fourth quarter, Teva continued its commercial efforts with ADASUVE in the U.S., increasing the number of hospitals who have completed the pharmacy & therapeutics committee review process and/or the REMS enrollment process.

 

    In December 2014, Alexza amended its commercial Manufacturing and Supply Agreement with Autoliv ASP, Inc. Autoliv manufactures chemical heat packages, a key component of Alexza’s single-dose Staccato system, including ADASUVE. The Amendment nullified the letter of termination received by Alexza in October 2013 and the parties extended the agreement through 2018. In addition, Alexza has the right to engage a second source supplier and implement a manufacturing line transfer to manufacture and supply the chemical heat packages from Autoliv to Alexza or its licensees.

 

Page 1 of 7


The following information was filed by Alexza Pharmaceuticals Inc. (ALXA) on Monday, March 9, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Alexza Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alexza Pharmaceuticals Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account